Kingworld Medicines Group Limited announced that based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2022 (the "Period") and the information currently available to the Board, the Group is expected to record an increase in the profit attributable to owners of the Company by approximately 20% to 25% for the Period as compared to the profit attributable to owners of the Company of RMB 19.5 million for the six months ended 30 June 2021 (the "Previous Period"). The Board considers that the increase in the profit attributable to owners of the Company was mainly due to an increase in (i) the gross profit from distribution of imported branded pharmaceutical and healthcare products in China by approximately 15% to 20%; and (ii) the share of profit of a joint venture by approximately 145% to 150% for the Period as compared to the Previous Period as a result of the market recovery from the outbreak of the COVID-19 pandemic (the "Pandemic").